# EYOUGENE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eyougene

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.eyougene.com
- Latest round: Series B (Jan 12, 2023)
- Investors on record: 2

## About

Based in Shanghai, China, and established in 2016, EYOUGENE is a biotechnology company that provides contract development and manufacturing organization (CDMO) services, and intermediates for medicals and materials.  It has  R&D centers in Shanghai, Xi'an, and Wuhan, and Shanghai R&D centres cover over 10,000 square meters. And it has production bases and formulation R&D platforms in  Gansu, Shandong, Shanxi, Jiangxi, and other places. Moreover, it has additional branches in Shenzhen, Germany, and the USA. Its medical clients include Wuxi AppTech, Jiangsu Hengrui Medicine Co.,Ltd., and Johnson & Johnson. And its material clients include BASF SE, NICCA, and Mitsubishi Chemical. 

EYOUGENE provides CDMO services for medicals and materials. The new materials include furandicarboxylic acid and 2-Hydroxy-6-naphthoic acid. The furandicarboxylic acid is used for packaging containers, barrier films, fiber materials, and bulletproof glass, and 2-Hydroxy-6-naphthoic acid is used for engineering plastics, organic pigments, and pharmaceutical organic intermediates. Biomedical include antiviral drugs, antitumor drugs, calciferol drugs, and hypoglycemic drugs.

## Funding rounds

- Series B, Jan 12, 2023 — LingDu Capital, Hangzhou Huadian Investment Management Co., Ltd.

## Investors

- LingDu Capital — Series B
- Hangzhou Huadian Investment Management Co., Ltd. — Series B